Urologic Oncology: seminars and original investigations

Journal

Publication Venue For

  • Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy.  40:104.e1-104.e7. 2022
  • The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.  39:831.e19-831.e27. 2021
  • Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.  39:295.e1-295.e8. 2021
  • Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy.  37:970-975. 2019
  • Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.  36:341.e1-341.e7. 2018
  • Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.  36:243.e1-243.e8. 2018
  • Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy.  36:241.e7-241.e13. 2018
  • Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis.  36:147-152. 2018
  • Obesity as defined by waist circumference but not body mass index is associated with higher renal mass complexity.  35:661.e1-661.e6. 2017
  • Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancer.  35:663.e15-663.e21. 2017
  • Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?.  35:34.e17-34.e25. 2017
  • Contemporary role of advanced imaging for bladder cancer staging.  34:124-133. 2016
  • Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.  33:425.e1-425.e6. 2015
  • Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.  33:204.e1-204.e7. 2015
  • Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.  33:202.e1-202.e7. 2015
  • Pathological characteristics and radiographic correlates of complex renal cysts.  32:1010-1016. 2014
  • Combining routine morphology, p16INK4a immunohistochemistry, and in situ hybridization for the detection of human papillomavirus infection in penile carcinomas: A tissue microarray study using classifier performance analyses.  32:171-177. 2014
  • Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance.  32:26.e25-26.e31. 2014
  • Minimal changes in the systemic immune response after nephrectomy of localized renal masses.  32:589-600. 2014
  • PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalation.  32:687-693. 2014
  • Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program.  32:23.e9-23.e13. 2014
  • Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.  32:501-508. 2014
  • Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis..  31:1283-1291. 2013
  • Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques.  31:572-575. 2013
  • Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.  30:428-433. 2012
  • Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: Results from CaPSURE™.  28:268-273. 2010
  • PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma.  27:525-528. 2009
  • Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: Report of a case, review of the literature, and analysis of chemokine receptor expression.  23:261-267. 2005
  • Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Rubin, MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer, MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM, Department of Pathology, Brigham and Women's Hospital, Boston, MA. Cancer Res 2004;64:3814–22.  22:436-437. 2004
  • Continuing trends in pathological stage migration in radical prostatectomy specimens.  22:300-306. 2004

    • International Standard Serial Number (issn)

  • 1078-1439

    • Electronic International Standard Serial Number (eissn)

  • 1873-2496